• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Earnings Beat Will Impact DaVita (DVA) Investors

    Simply Wall St·11/01/2026 04:48:31
    Listen to the news
    • DaVita reported third quarter 2026 revenue of US$3,578.13 million and net income of US$222.93 million, with earnings per share from continuing operations above the prior year, helped by Integrated Kidney Care and international performance.
    • The company is leaning on Integrated Kidney Care value based contracts and advanced hemodialyzer rollout to support earnings, while continuing heavy technology investment.
    • We will look at how DaVita's investment narrative around integrated kidney care is affected by this strong third quarter earnings performance.

    Scan how DaVita's latest earnings and healthcare focus stack up against other potential opportunities by reviewing list of solid balance sheet and fundamentals (24 results) in the same market backdrop.

    DaVita Investment Narrative Recap

    To own DaVita, you need to be comfortable with a kidney care operator that leans heavily on integrated kidney care economics and incremental efficiency gains rather than rapid top line expansion. The latest quarter, with earnings per share from continuing operations above the prior year, supports the idea that Integrated Kidney Care and international operations can help offset reimbursement and payer mix pressure in U.S. dialysis, at least near term.

    The key near term catalyst remains execution in Integrated Kidney Care value based contracts and the national rollout of expanded hemodialyzers. Both affect revenue quality and cost of care. The biggest risk still sits in U.S. dialysis profitability, where reimbursement updates, payer shifts and rising technology and support costs could dilute the benefit of the current earnings strength if not tightly controlled.

    The recent settlement related to the April 2025 ransomware incident, with payments not to exceed US$15,000,000, adds an operational and reputational thread to your thesis. The proposed settlement offers cash payments, multi year credit monitoring and reimbursement of documented out of pocket losses, subject to court approval in February 2027, which helps quantify at least part of the near term financial exposure.

    For an investor watching catalysts, this cyber episode matters less for its direct cost and more for what it indicates about execution risk around DaVita’s US$1b technology modernization. A business that depends increasingly on data driven Integrated Kidney Care contracts and digital tools needs visibly strong security and resilience. Any repeat incident or higher than expected ongoing security spend could reduce the operating leverage that DaVita is trying to build through that technology program.

    DaVita's narrative projects US$16.1b revenue and US$1.1b earnings by 2029. This assumes 4.6% yearly revenue growth and an earnings increase of about US$277.5m from US$822.5m today.

    Uncover why DaVita's fair value indicates a 17% potential upside to its current price. This represents a discount that could narrow quickly if sentiment turns.

    NYSE:DVA 1-Year Stock Price Chart
    NYSE:DVA 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate angle on DaVita focuses on Integrated Kidney Care volatility. The most bearish analysts were penciling in only about 2.4% annual revenue growth to roughly US$15.0b by 2029 and earnings near US$1.1b. That is a far more cautious script, and this latest quarterly surprise may push some of those views to evolve.

    Explore 3 other DaVita fair value estimates, including one that suggests it could be worth just $218.71.

    Form Your Own Verdict

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Ideas Beyond DaVita?

    If DaVita's earnings story has sharpened your thinking, it can help to line it up against other companies with different balance sheet profiles, income streams and risk levels. The Simply Wall St Screener lets you filter for the traits that matter most to you, so you can compare this kidney care operator with a broader set of candidates.

    • For investors who want potential upside paired with robust fundamentals, review a curated 19 high quality undiscovered gems that may not yet be widely followed by the market.
    • If capital preservation and lower volatility sit higher on your list, filter for 29 resilient stocks with low risk scores and see which businesses score well on resilience metrics.
    • For readers focused on income and cash returns, scan 5 dividend fortresses and weigh their yields and balance sheets against what you see at DaVita.